All In MedTech

Device Trial Radar · NCT07916350

A Study of the Safety and Effectiveness of a Compound Steep-Pulse Therapy Apparatus for Malignant Liver Tumors

A Prospective, Parallel-Group, Randomized, Controlled, Noninferiority, Multicenter Study Evaluating the Safety and Efficacy of a Compound Steep-Pulse Therapy Apparatus for Malignant Liver Tumors

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 181 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

181

Actual

Start

Dec 28, 2021

Primary completion

Jun 26, 2024

Study completion Dec 6, 2024

Sponsor

Lead sponsor
REMD Medical TechnologyNot on our public-company list
Sponsor type
Industry
Collaborators
Beijing YouAn Hospital; Henan Cancer Hospital; Nanfang Hospital, Southern Medical University; Beijing Ditan Hospital; First Affiliated Hospital of Zhejiang University; The First School of Clinical Medicine of Binzhou Medical University; RenJi Hospital
First posted
Nov 4, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective, multicenter, randomized, parallel-group, open-label, noninferiority study compares the safety and efficacy of the Compound Steep-Pulse Therapy Apparatus with radiofrequency ablation in adults with malignant liver tumors. Eligible participants are randomly assigned in a 1:1 ratio to the test group or the control group using a web-based central randomization system, with stratification by tumor diameter and tumor type. The primary outcome is the ablation success rate at 1 month after treatment, assessed by contrast-enhanced computed tomography or magnetic resonance imaging under blinded conditions. Secondary outcomes include ablation success at 3 months, complete ablation rates, tumor response, local recurrence-free rates, procedure-related complications, console operability, and system stability. Safety is evaluated through adverse events and laboratory assessments.

Conditions

  • Malignant Liver Tumors

Interventions

  • Compound Steep-Pulse Therapy Apparatus (HFMP-02)Device

    The Compound Steep-Pulse Therapy Apparatus (Nortion, model HFMP-02) delivers microsecond-level, bipolar, high-intensity composite pulses to solid tumors to induce irreversible electroporation (IRE)-mediated cell death. In this trial it is used for local ablation of liver malignant tumors.

  • Cool-tip RF Ablation System (CTRF220)Device

    The Cool-tip RF Ablation System (Covidien/Medtronic, model CTRF220) is a radiofrequency ablation generator indicated for coagulation and ablation of tissue during percutaneous, laparoscopic, and surgical procedures. In this trial it serves as the active comparator for local ablation of liver malignant tumors.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Ablation success rate at 1 month after ablationTime frame: 1 month after ablation

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nortion Medical Technology Co., Ltd

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.